The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
Open accessAbstract
Monoclonal antibodies (mAbs) are a crucial asset for human health and modern medicine, however, the repeated administration of mAbs can be highly immunogenic. Drug immunogenicity manifests in the generation of anti-drug antibodies (ADAs), and some mAbs show immunogenicity in up to 70% of patients. ADAs can alter a drug's pharmacokinetic and pharmacodynamic properties, reducing drug efficacy. In more severe cases, ADAs can neutralize the drug's therapeutic effects or cause severe adverse events to the patient. While some contributing factors to ADA formation are known, the molecular mechanisms of how therapeutic mAbs elicit ADAs are not completely clear. Accurate ADA detection is necessary to provide clinicians with sufficient information for patient monitoring and clinical intervention. However, ADA assays present unique challenges because both the analyte and antigen are antibodies, so most assays are cumbersome, costly, time consuming, and lack standardization. This review will discuss aspects related to ADA formation following mAb drug administration. First, we will provide an overview of the prevalence of ADA formation and the available diagnostic tools for their detection. Next, we will review studies that support possible molecular mechanisms causing the formation of ADA. Finally, we will summarize recent approaches used to decrease the propensity of mAbs to induce ADAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Making antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Danger signals: SOS to the immune system
Gallucci, S., & Matzinger, P. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00191-6 · Cited by 1,204
Pasparakis, M., Alexopoulou, L., Episkopou, V, & Kollias, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.4.1397 · Cited by 1,160
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood · doi:10.1182/blood-2009-04-217604 · Cited by 1,122
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
From the American Association of Neurological Surgeons (AANS), A. S. O. N. (., Sacks, D., Baxter, B., Campbell, B. C. V., Carpenter, J. S., Cognard, C., Dippel, D., Eesa, M., Fischer, U., Hausegger, K., et al. (2018) · International Journal of Stroke · doi:10.1177/1747493018778713 · Cited by 915
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1602615 · Cited by 858
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N. S., Louder, M., McKee, K., et al. (2011) · Science · doi:10.1126/science.1207532 · Cited by 784
Bartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 782
The who, how and where of antigen presentation to B cells
Batista, F. D., & Harwood, N. E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2454 · Cited by 775
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
Self-citationSacks, D., Baxter, B., Campbell, B. C. V., Carpenter, J. S., Cognard, C., Dippel, D., Eesa, M., Fischer, U., Hausegger, K., Hirsch, J. A., et al. (2018) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2017.11.026 · Cited by 686
The promise and challenge of high-throughput sequencing of the antibody repertoire
Georgiou, G., Ippolito, G. C., Beausang, J., Busse, C. E., Wardemann, H., & Quake, S. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2782 · Cited by 652
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Ben-Horin, S., & Chowers, Y. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04612.x · Cited by 620
From the American Association of Neurological Surgeons (AANS), A. S. O. N. (., Sacks, D., Baxter, B., Campbell, B. C. V., Carpenter, J. S., Cognard, C., Dippel, D., Eesa, M., Fischer, U., Hausegger, K., et al. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5638 · Cited by 599
Immunogenicity of protein therapeutics
De Groot, A. S., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., & Khazaeli, M. B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4220 · Cited by 524
Ober, R. J., Radu, C. G., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 501
The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design
Fleri, W., Paul, S., Dhanda, S. K., Mahajan, S., Xu, X., Peters, B., & Sette, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00278 · Cited by 500
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., & Morgan, A. C. (1985) · PubMed · Cited by 488
(2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.00607.x · Cited by 472
The Increasingly Human and Profitable Monoclonal Antibody Market
Grilo, A. L., & Mantalaris, A. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.05.014 · Cited by 462
Herceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Glanville, J., Zhai, W., Berka, J., Telman, D., Huerta, G., Mehta, G. R., Ni, I., Mei, L., Sundar, P. D., Day, G. M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909775106 · Cited by 440
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 438
Sazonovs, A., Kennedy, N. A., Moutsianas, L., Heap, G. A., Rice, D. L., Reppell, M., Bewshea, C. M., Chanchlani, N., Walker, G. J., Perry, M. H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.041 · Cited by 423
B1b Lymphocytes Confer T Cell-Independent Long-Lasting Immunity
Alugupalli, K. R., Leong, J. M., Woodland, R. T., Muramatsu, M., Honjo, T., & Gerstein, R. M. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.019 · Cited by 411
Garcês, S., Demengeot, J., & Benito-Garcia, E. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202220 · Cited by 411
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire
DeKosky, B. J., Ippolito, G. C., Deschner, R. P., Lavinder, J. J., Wine, Y., Rawlings, B. M., Varadarajan, N., Giesecke, C., Dörner, T., Andrews, S. F., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2492 · Cited by 410 · cited 1×
“Previous studies were able to obtain VH and VL chain pairing from isolated plasmablasts (PB) in immunized mice (34, 45, 46) and antigen-specific PB from tetanus-vaccinated human patients (33).”
Self-citationActivation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
De Groot, A. S., Moise, L., McMurry, J. A., Wambre, E., Van Overtvelt, L., Moingeon, P., Scott, D. W., & Martin, W. (2008) · Blood · doi:10.1182/blood-2008-02-138073 · Cited by 392
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372
In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire
DeKosky, B. J., Kojima, T., Rodin, A., Charab, W., Ippolito, G. C., Ellington, A. D., & Georgiou, G. (2015) · Nature Medicine · doi:10.1038/nm.3743 · Cited by 357
Self-citationVincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., Mendez, M. J., Abderrahim, H., Noguchi, M., Smith, D. H., Zeng, Y., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-13 · Cited by 355
Assessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
Overview of methodologies for T-cell receptor repertoire analysis
Rosati, E., Dowds, C. M., Liaskou, E., Henriksen, E. K. K., Karlsen, T. H., & Franke, A. (2017) · BMC Biotechnology · doi:10.1186/s12896-017-0379-9 · Cited by 322
T-independent type II immune responses generate memory B cells
Obukhanych, T. V., & Nussenzweig, M. C. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052036 · Cited by 307
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
Pyzik, M., Rath, T., Lencer, W. I., Baker, K., & Blumberg, R. S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403014 · Cited by 298
Alas, S., & Bonavida, B. (2001) · PubMed · Cited by 293
Reddy, S. T., Ge, X., Miklos, A. E., Hughes, R. A., Kang, S. H., Hoi, K. H., Chrysostomou, C., Hunicke-Smith, S. P., Iverson, B. L., Tucker, P. W., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1673 · Cited by 292
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
Cox, A. L., Thompson, S. A. J., Jones, J. L., Robertson, V. H., Hale, G., Waldmann, H., Compston, D. A. S., & Coles, A. J. (2005) · European Journal of Immunology · doi:10.1002/eji.200535075 · Cited by 291
The Generative Grammar of the Immune System
Jerne, N. K. (1985) · Science · doi:10.1126/science.4035345 · Cited by 281
Lee, J., Boutz, D. R., Chromikova, V., Joyce, M. G., Vollmers, C., Leung, K., Horton, A. P., DeKosky, B. J., Lee, C.-H., Lavinder, J. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4224 · Cited by 277
Self-citationT-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
What's fueling the biotech engine—2012 to 2013
(Rob) Aggarwal, S. (2014) · Nature Biotechnology · doi:10.1038/nbt.2794 · Cited by 254
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Presta, L. G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.026 · Cited by 246
Lavinder, J. J., Wine, Y., Giesecke, C., Ippolito, G. C., Horton, A. P., Lungu, O. I., Hoi, K. H., DeKosky, B. J., Murrin, E. M., Wirth, M. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317793111 · Cited by 242
Self-citationGupta, S., Indelicato, S. R., Jethwa, V., Kawabata, T., Kelley, M., Mire-Sluis, A. R., Richards, S. M., Rup, B., Shores, E., Swanson, S. J., et al. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.12.004 · Cited by 241
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
Baker, D., Herrod, S. S., Alvarez-Gonzalez, C., Giovannoni, G., & Schmierer, K. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0676 · Cited by 241
Manoury, B., Mazzeo, D., Fugger, L., Viner, N., Ponsford, M., Streeter, H., Mazza, G., Wraith, D. C., & Watts, C. (2002) · Nature Immunology · doi:10.1038/ni754 · Cited by 212
Epitope dominance, competition and T cell affinity maturation
Kedl, R. M., Kappler, J. W., & Marrack, P. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00009-2 · Cited by 209
Mrowietz, U., Leonardi, C. L., Girolomoni, G., Toth, D., Morita, A., Balki, S. A., Szepietowski, J. C., Regnault, P., Thurston, H., & Papavassilis, C. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.04.011 · Cited by 208
Ben-Horin, S., Yavzori, M., Katz, L., Kopylov, U., Picard, O., Fudim, E., Coscas, D., Bar-Meir, S., Goldstein, I., & Chowers, Y. (2011) · Gut · doi:10.1136/gut.2009.201533 · Cited by 203
Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles
Anderson, P. J. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.005 · Cited by 202
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
García-Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z., Ronga, P., Witzler, P., & Stintzing, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00849 · Cited by 201
Immunogenicity and autoimmunity during anti-TNF therapy
Atzeni, F., Talotta, R., Salaffi, F., Cassinotti, A., Varisco, V., Battellino, M., Ardizzone, S., Pace, F., & Sarzi-Puttini, P. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.10.021 · Cited by 196
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
Baldo, B. (2013) · OncoImmunology · doi:10.4161/onci.26333 · Cited by 191
Svenson, M., Geborek, P., Saxne, T., & Bendtzen, K. (2007) · Rheumatology · doi:10.1093/rheumatology/kem261 · Cited by 189
Differential Tolerance Is Induced in T Cells Recognizing Distinct Epitopes of Myelin Basic Protein
Harrington, C. J., Paez, A., Hunkapiller, T., Mannikko, V., Brabb, T., Ahearn, M., Beeson, C., & Goverman, J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80562-2 · Cited by 179
Zhou, Q., & Qiu, H. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.11.029 · Cited by 169
Belimumab: A Review in Systemic Lupus Erythematosus
Blair, H. A., & Duggan, S. T. (2018) · Drugs · doi:10.1007/s40265-018-0872-z · Cited by 161
Differential effect of drug interference in immunogenicity assays
Hart, M. H., de Vrieze, H., Wouters, D., Wolbink, G.-J., Killestein, J., de Groot, E. R., Aarden, L. A., & Rispens, T. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.07.019 · Cited by 160
Rau, R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii70 · Cited by 159
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
Koren, M. J., Sabatine, M. S., Giugliano, R. P., Langslet, G., Wiviott, S. D., Ruzza, A., Ma, Y., Hamer, A. W., Wasserman, S. M., & Raal, F. J. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1024 · Cited by 159
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
van Brummelen, E. M. J., Ros, W., Wolbink, G., Beijnen, J. H., & Schellens, J. H. M. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0061 · Cited by 158
Schulman, E. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.supplement_1.2103025 · Cited by 148
Koren, E., Groot, A. S. D., Jawa, V., Beck, K. D., Boone, T., Rivera, D., Li, L., Mytych, D. T., Koscec, M., Weeraratne, D. K., et al. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.03.544 · Cited by 143
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic
Cohenuram, M. K., & Saif, M. W. (2006) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32800feecb · Cited by 141
Functional interrogation and mining of natively paired human VH:VL antibody repertoires
Wang, B., DeKosky, B. J., Timm, M. R., Lee, J., Normandin, E., Misasi, J., Kong, R., McDaniel, J. R., Delidakis, G., Leigh, K. E., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4052 · Cited by 140
Self-citationMolecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response
Wine, Y., Boutz, D. R., Lavinder, J. J., Miklos, A. E., Hughes, R. A., Hoi, K. H., Jung, S. T., Horton, A. P., Murrin, E. M., Ellington, A. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213737110 · Cited by 139
Self-citationRole of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies
Fehr, T. H., Bachmann, M. F., Bucher, E. M., Kalinke, U., Padova, F. E. D., Lang, A. B., Hengartner, H., & Zinkernagel, R. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.10.1785 · Cited by 135
Lei, S., Lei, H., Green, D., Gill, J. C., Conti‐Fine, B. M., & Reding, M. T. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613257 · Cited by 131
Ungar, B., Kopylov, U., Yavzori, M., Fudim, E., Picard, O., Lahat, A., Coscas, D., Waterman, M., Haj-Natour, O., Orbach-Zingboim, N., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.11.050 · Cited by 126
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
Lim, H., Lee, S. H., Lee, H., Lee, J., Son, J., Shin, W., & Heo, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030768 · Cited by 116
Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
Burmester, G. R., Choy, E., Kivitz, A., Ogata, A., Bao, M., Nomura, A., Lacey, S., Pei, J., Reiss, W. G., Pethoe-Schramm, A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210297 · Cited by 113
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
Dunn, N., Juto, A., Ryner, M. L., Manouchehrinia, A., Piccoli, L., Fink, K., Piehl, F., & Fogdell‐Hahn, A. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517720044 · Cited by 112
Taillardet, M., Haffar, G., Mondière, P., Asensio, M., Gheit, H., Burdin, N., Defrance, T., & Genestier, L. (2009) · Blood · doi:10.1182/blood-2009-01-200014 · Cited by 111
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
Deisseroth, A., Ko, C., Nie, L., Zirkelbach, J. F., Zhao, L. Y., Bullock, J. M., Mehrotra, N., Valle, P. D., Saber, H., Sheth, C. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1678 · Cited by 110
Immunogenicity and other problems associated with the use of biopharmaceuticals
Tovey, M. G., & Lallemand, C. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611406318 · Cited by 108
Rajan, A., Kim, C., Heery, C. R., Guha, U., & Gulley, J. L. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1175694 · Cited by 104
Wilson, A. S., Peel, C., Wang, Q., Pananos, A. D., & Kim, R. B. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15563 · Cited by 103
Lallemand, C., Kavrochorianou, N., Steenholdt, C., Bendtzen, K., Ainsworth, M. A., Méritet, J., Blanchard, B., Lebon, P., Taylor, P. C., Charles, P. J., et al. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.08.022 · Cited by 99
Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
Paul, S., Carla-Moreau, A., Tedesco, É. D., Rinaudo, M., Phelip, J., Genin, C., Peyrin‐Biroulet, L., & Roblin, X. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000037 · Cited by 99
Epitome: database of structure-inferred antigenic epitopes
Schlessinger, A., Ofran, Y., Yachdav, G., & Rost, B. (2005) · Nucleic Acids Research · doi:10.1093/nar/gkj053 · Cited by 97
Immunogenicity of rituximab in patients with severe pemphigus
Schmidt, E., Hennig, K., Mengede, C., Zillikens, D., & Kromminga, A. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.05.007 · Cited by 96
Banugaria, S. G., Prater, S. N., McGann, J. K., Feldman, J. D., Tannenbaum, J. A., Bailey, C., Gera, R., Conway, R. L., Viskochil, D. H., Kobori, J. A., et al. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.110 · Cited by 94
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
Doevendans, E., & Schellekens, H. (2019) · Antibodies · doi:10.3390/antib8010021 · Cited by 93
Zoghbi, J., Xu, Y., Grabert, R. C., Theobald, V., & Richards, S. M. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.08.002 · Cited by 92
Yin, L., Chen, X., Vicini, P., Rup, B. J., & Hickling, T. P. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.03.002 · Cited by 91
Antidrug Antibodies in Patients Treated with Alirocumab
Roth, E. M., Goldberg, A. C., Catapano, A. L., Torri, A., Yancopoulos, G. D., Stahl, N., Brunet, A., Lecorps, G., & Colhoun, H. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616623 · Cited by 90
Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors
Hamze, M., Meunier, S., Karle, A. C., Gdoura, A., Goudet, A., Szely, N., Pallardy, M. J., Carbonnel, F., Spindeldreher, S., Xavier Mariette, A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00500 · Cited by 88
Ozkaynak, M. F., Gilman, A. L., London, W. B., Naranjo, A. H., Diccianni, M. B., Tenney, S. C., Smith, M. A., Messer, K. S., Seeger, R. C., Reynolds, C. P., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01355 · Cited by 87
Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
Li, Z., Richards, S., Surks, H. K., Jacobs, A., & Panzara, M. A. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13208 · Cited by 87
Karle, A. C., Spindeldreher, S., & Kolbinger, F. (2016) · mAbs · doi:10.1080/19420862.2015.1136761 · Cited by 86
Kumar, S., Singh, S. K., Wang, X., Rup, B., & Gill, D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0414-9 · Cited by 85
Saggy, I., Wine, Y., Shefet-Carasso, L., Nahary, L., Georgiou, G., & Benhar, I. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs060 · Cited by 82
Self-citationLofgren, J. A., Wala, I., Koren, E., Swanson, S. J., & Jing, S. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.10.007 · Cited by 81
Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context
Bloem, K., Hernández‐Breijo, B., Martínez‐Feito, A., & Rispens, T. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000404 · Cited by 81
Next generation deep sequencing and vaccine design: today and tomorrow
Luciani, F., Bull, R. A., & Lloyd, A. R. (2012) · Trends in biotechnology · doi:10.1016/j.tibtech.2012.05.005 · Cited by 77
Agrawal, S., Statkevich, P., Bajaj, G., Feng, Y., Saeger, S., Desai, D. D., Park, J., Waxman, I. M., Roy, A., & Gupta, M. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.818 · Cited by 76
Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
Thomas, K., Eisele, J., Rodriguez-Leal, F. A., Hainke, U., & Ziemssen, T. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000228 · Cited by 75
Immunogenicity of biological therapeutics: from assay to patient
Krieckaert, C. L. M., Rispens, T., & Wolbink, G. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283521c4e · Cited by 73
Proteomic Identification of Monoclonal Antibodies from Serum
Boutz, D. R., Horton, A. P., Wine, Y., Lavinder, J. J., Georgiou, G., & Marcotte, E. M. (2014) · Analytical Chemistry · doi:10.1021/ac4037679 · Cited by 73
Self-citationCassotta, A., Mikol, V., Bertrand, T., Pouzieux, S., Parc, J. L., Ferrari, P., Dumas, J., Auer, M., Deisenhammer, F., Gastaldi, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0568-2 · Cited by 70
Shikh, M. E. E., Sayed, R. M. E., Szakal, A. K., & Tew, J. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802317 · Cited by 67
Immunological aspects of inhibitor development
Reding, M. T. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01363.x · Cited by 64
Rosenfeld, R., Valensi, M., & Benhar, I. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.10.053 · Cited by 64
Drug allergens and food—the cetuximab and galactose-α-1,3-galactose story
Berg, E. A., Platts‐Mills, T. A. E., & Commins, S. P. (2013) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2013.11.014 · Cited by 63
Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics
Tatarewicz, S. M., Miller, J. M., Swanson, S. J., & Moxness, M. S. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.03.012 · Cited by 61
Kverneland, A. H., Enevold, C., Donia, M., Bastholt, L., Svane, I. M., & Nielsen, C. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424674 · Cited by 61
Immunogenicity of pembrolizumab in patients with advanced tumors
van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0663-4 · Cited by 57
Vaisman-Mentesh, A., Rosenstein, S., Yavzori, M., Dror, Y., Fudim, E., Ungar, B., Kopylov, U., Picard, O., Kigel, A., Ben-Horin, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02921 · Cited by 54
Self-citationInefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation
de Vries, M. K., Wolbink, G., Stapel, S. O., de Groot, E. R., Dijkmans, B. A. C., Aarden, L. A., & van der Horst-Bruinsma, I. E. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057745 · Cited by 54
Design and engineering of deimmunized biotherapeutics
Griswold, K. E., & Bailey‐Kellogg, C. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.06.003 · Cited by 54
Biologics and biosimilars: what, why and how?
Chan, J. C. N., & Chan, A. T. �. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000180 · Cited by 50
A Survey of Applications of Biological Products for Drug Interference of Immunogenicity Assays
Wang, Y., Fang, L., Zhou, L., Wang, J., & Ahn, H. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0833-2 · Cited by 48
Pecoraro, V. L., Santis, E. D., Melegari, A., & Trenti, T. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.002 · Cited by 48
Ortega, H. G., Lemière, C., Llanos, J., Forshag, M. S., Price, R. G., Albers, F. C., Yancey, S. W., & Castro, M. (2019) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-019-0348-z · Cited by 46
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben‐Horin, S., Heap, G., Ahmad, T., Kim, H., Kwon, T., & Chowers, Y. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1091307 · Cited by 43
Gokemeijer, J., Jawa, V., & Mitra‐Kaushik, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0143-z · Cited by 43
Chen, Q., Hu, C., Liu, Y., Song, R., Zhu, W., Zhao, H., Nino, A., Zhang, F., & Liu, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197984 · Cited by 43
Infliximab–Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies
Bar‐Yoseph, H., Pressman, S., Blatt, A., Gerassy-Vainberg, S., Maimon, N., Starosvetsky, E., Ungar, B., Ben‐Horin, S., Shen-Orr, S. S., & Chowers, Y. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.08.009 · Cited by 42
Talotta, R., Rucci, F., Canti, G. L., & Scaglione, F. (2019) · Immunotherapy · doi:10.2217/imt-2018-0081 · Cited by 41
Vultaggio, A., Petroni, G., Pratesi, S., Nencini, F., Cammelli, D., Milla, M., Prignano, F., Annese, V., Romagnani, S., Maggi, E., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12858 · Cited by 39
Kimball, A. B., Kerbusch, T., van Aarle, F., Kulkarni, P., Li, Q., Blauvelt, A., Papp, K. A., Reich, K., & Montgomery, D. L. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17918 · Cited by 30
Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases.
Spinelli, F. R., & Valesini, G. (2014) · PubMed · Cited by 27
Arnoult, C., Brachet, G., Castaneda, D. C., Azzopardi, N., Passot, C., Desvignes, C., Paintaud, G., Heuzé‐Vourc'h, N., Watier, H., & Gouilleux‐Gruart, V. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601246 · Cited by 27
Immunogenicity and skin clearance recapture in clinical studies of brodalumab
Bagel, J., Lebwohl, M., Israel, R. J., & Jacobson, A. A. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.094 · Cited by 26
Nagy, C. F., Leach, T. S., King, A., et al. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.410 · Cited by 22
Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
Li, Y., Wang, B., Chia, Y. L., & Roskos, L. K. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00738-4 · Cited by 19
Hillmen, P., Muus, P., Szer, J., Hill, A., Höchsmann, B., Kulasekararaj, A. G., Risitano, A. M., Neste, E. V. D., Liljeholm, M., Ebrahim, K. S., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24280 · Cited by 16
Hernández‐Breijo, B., Chaparro, M., Cano-Martínez, D., Guerra, I., Iborra, M., Cabriada, J. L., Bujanda, L., Taxonera, C., García-Sánchez, V., Marín‐Jiménez, I., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.019 · Cited by 13
Monitoring Phage Biopanning by Next-Generation Sequencing
Vaisman‐Mentesh, A., & Wine, Y. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7447-4_26 · Cited by 12
Self-citationPassey, C., Mora, J. R., Dodge, R. W., Gibiansky, L. V., Sheng, J., Roy, A., Bello, A., & Gupta, M. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0033-9 · Cited by 10
Said, R., & Tsimberidou, A. M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1377178 · Cited by 8
Saffari, F., Jafarzadeh, A., Khandani, B. K., Saffari, F., Soleimanyamoli, S., & Mohammadi, M. M. (2018) · International Journal of Cancer Management · doi:10.5812/ijcm.64983 · Cited by 6
Cited by
Mason, D. M., Friedensohn, S., Weber, C. R., Jordi, C., Wagner, B., Meng, S. M., Ehling, R. A., Bonati, L., Dahinden, J., Gainza, P., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00699-9 · Cited by 308
Fan, X., Jiang, K., Geng, F., Lu, W., & Wei, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114864 · Cited by 33
(2025) · doi:10.1016/j.antiviral.2025.106235 · Cited by 1
Metadata
- Authors
- Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B. J., & Wine, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-18
- Volume
- 11
- Pages
- 1951-1951
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3062976875
- Cited by
- 292
- References
- 152
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.